Revefenacin Patent Expiration
Revefenacin is Used for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). It was first introduced by Mylan Ireland Ltd
Revefenacin Patents
Given below is the list of patents protecting Revefenacin, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Yupelri | US11484531 | Methods for treating chronic obstructive pulmonary disease | Oct 23, 2039 | Mylan Ireland Ltd |
Yupelri | US12048692 | Methods for treating chronic obstructive pulmonary disease | Aug 29, 2039 | Mylan Ireland Ltd |
Yupelri | US8541451 | Crystalline freebase forms of a biphenyl compound | Aug 25, 2031 | Mylan Ireland Ltd |
Yupelri | US10550081 | Crystalline freebase forms of a biphenyl compound | Jul 14, 2030 | Mylan Ireland Ltd |
Yupelri | US11008289 | Crystalline freebase forms of a biphenyl compound | Jul 14, 2030 | Mylan Ireland Ltd |
Yupelri | US11691948 | Crystalline freebase forms of a biphenyl compound | Jul 14, 2030 | Mylan Ireland Ltd |
Yupelri | US11858898 | Crystalline freebase forms of a biphenyl compound | Jul 14, 2030 | Mylan Ireland Ltd |
Yupelri | US9765028 | Crystalline freebase forms of a biphenyl compound | Jul 14, 2030 | Mylan Ireland Ltd |
Yupelri | US7288657 | Biphenyl compounds useful as muscarinic receptor antagonists | Oct 31, 2028 | Mylan Ireland Ltd |
Yupelri | US10106503 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US10343995 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US11247969 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US7491736 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US7521041 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US7550595 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US7585879 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US7910608 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US8034946 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US8053448 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
Yupelri | US8273894 | Biphenyl compounds useful as muscarinic receptor antagonists | Mar 10, 2025 | Mylan Ireland Ltd |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Revefenacin's patents.
Latest Legal Activities on Revefenacin's Patents
Given below is the list recent legal activities going on the following patents of Revefenacin.
Activity | Date | Patent Number |
---|---|---|
Email Notification Critical | 03 May, 2024 | US7585879 |
Change in Power of Attorney (May Include Associate POA) Critical | 03 May, 2024 | US7585879 |
Email Notification Critical | 25 Apr, 2024 | US7288657 |
Change in Power of Attorney (May Include Associate POA) Critical | 25 Apr, 2024 | US7288657 |
Payment of Maintenance Fee, 12th Year, Large Entity | 25 Mar, 2024 | US8273894 |
Notice of Final Determination -Election Required | 22 Mar, 2024 | US7585879 |
Notice of Final Determination -Election Required | 22 Mar, 2024 | US7288657 |
Recordation of Patent eCertificate of Correction | 20 Feb, 2024 | US11858898 |
Mail Patent eCofC Notification | 20 Feb, 2024 | US11858898 |
Email Notification Critical | 20 Feb, 2024 | US11858898 |